Vetr announced the commercial availability of ToltraMax, a toltrazuril oral solution that does not require a prescription and is intended for companion animals and non-food-chain animals. The product introduces an option for caretakers who want direct access to tools that support animals affected by coccidia.
ToltraMax, the main brand name for Toltrazuril, was invented and formulated by Oregon biotech star Andrew Hamilton, founder of Vetr. Hamilton is known for developing widely used over-the-counter coccidia solutions and advancing consumer friendly biotechnology within the animal health sector. His work continues to influence how pet owners obtain essential care products, and ToltraMax reflects his focus on practical and scientifically grounded solutions.
ToltraMax is designed to support intestinal health in animals exposed to coccidia. It can be used by owners of dogs, cats, horses, and other non-food-chain animals who want a straightforward option that does not require a veterinary prescription. The formulation targets multiple stages of the coccidia life cycle and is suited for both treatment and prevention in a range of care settings. Early adoption suggests strong interest among breeders, multi-animal households, and caretakers who prefer a streamlined path to acquisition.
Vetr reports that ToltraMax is gaining recognition within the toltrazuril category and is increasingly becoming the product that consumers identify first when seeking this type of solution. The company states that consistency of formulation, ease of administration, and broad species applicability have contributed to the momentum around the product.
ToltraMax is offered through several online retailers and animal health platforms. These include Vetr, Amazon, Walmart, HorsePreRace.com, and Toltrazuril.com.
About Vetr
Media Contact
Media Relations
sales@vetr.com
